TransMedics Stock: Waiting On 2027 Catalysts (NASDAQ:TMDX)
TransMedics' clinical trials are only moving forward slowly, potentially delaying a critical growth catalyst. Read why TMDX stock is upgraded to a buy.
We can't find the internet
Attempting to reconnectSomething went wrong!
Attempting to reconnectTransMedics' clinical trials are only moving forward slowly, potentially delaying a critical growth catalyst. Read why TMDX stock is upgraded to a buy.